Financial Comparison: X4 Pharmaceuticals (XFOR) vs. Its Peers

X4 Pharmaceuticals (NASDAQ:XFOR) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare X4 Pharmaceuticals to similar companies based on the strength of its earnings, valuation, profitability, risk, dividends, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares X4 Pharmaceuticals and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11 million	-$79.20 million	-2.70
X4 Pharmaceuticals Competitors	$691.14 million	$10.43 million	-10.13

X4 Pharmaceuticals’ competitors have higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares X4 Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
X4 Pharmaceuticals Competitors	-9,046.59%	-199.78%	-30.61%

Volatility and Risk

X4 Pharmaceuticals has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals’ competitors have a beta of 1.10, suggesting that their average stock price is 10% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for X4 Pharmaceuticals and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1	1	4	0	2.50
X4 Pharmaceuticals Competitors	9789	15069	45339	1572	2.54

X4 Pharmaceuticals currently has a consensus target price of $11.25, suggesting a potential upside of 247.22%. As a group, “Biotechnology” companies have a potential upside of 94.11%. Given X4 Pharmaceuticals’ higher possible upside, equities analysts clearly believe X4 Pharmaceuticals is more favorable than its competitors.

Institutional & Insider Ownership

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

X4 Pharmaceuticals competitors beat X4 Pharmaceuticals on 7 of the 13 factors compared.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.